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Objectives: Previous studies have demonstrated gaps in achievement of low-density lipoprotein-cholesterol (LDL-C)
goals among patients at very high cardiovascular risk. We aimed to investigate lipid treatment patterns, rates and
predictors of lipid targets attainment, in such outpatients in an urban area of Greece.
Methods: This was a prospective observational study, conducted in 19 outpatient clinics of Western Greece. We
recruited patients with established cardiovascular disease (CVD) and/or diabetes mellitus (DM), previously (at least
3 months before baseline assessment) untreated with any lipid lowering medication. Lipid profile assessment was
performed at baseline (prior to lipid-lowering treatment initiation) and at follow-up. Lipid lowering treatment choice
was at physicians’ discretion and was kept constant until follow-up.
Results: We recruited 712 patients with a mean age 61.4 ± 10.4 years, 68.0% males, 43.0% with DM, 64.7% with prior
coronary artery disease-CAD. In total, 237/712 (33.3%) of prescribed regimens were of high or very high LDL-C
lowering efficacy and out of them 113/237 (47.7%) comprised a combination of statin and ezetimibe. At follow-up
the primary target of LDL-C < 70 mg/dL (1.8 mmol/L) was achieved in 71(10.0%) patients. The secondary target of
non-HDL-C < 100 mg/dL (2.6 mmol/L) in the subgroup of patients with DM or increased triglycerides levels
(>150 mg/dl or 1.7 mmol/L) was achieved in 45(11.6%) of patients. In multivariate logistic regression analysis
(AUC = 0.71, 95% CIs 0.65-0.77, p < 0.001) male gender, smoking, baseline LDL-C and very high potency LDL-C
lowering regimen emerged as independent predictors of LDL-C goal attainment (OR = 1.88, 95% CIs 1.03-3.44,
p = 0.04, OR = 0.57, 95% CIs 0.33-0.96, p = 0.04, OR = 0.98, 95% CIs 0.98-0.99, p < 0.001 and OR = 2.21, 95% CIs
1.15-4.24, p = 0.02 respectively).
Conclusions: First-line management of dyslipidemia among very-high cardiovascular risk outpatients in Western
Greece is unsatisfactory, with the majority of treated individuals failing to attain the LDL-C and non-HDL-C targets.
This finding points out the need for intensification of statin treatment in such patients.
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Cardiovascular disease (CVD) is the leading cause of global
mortality, accounting for more deaths annually than any
other cause [1]. Modification of the risk factors related to
CVD, such as dyslipidemia, smoking, or a sedentary life-
style, has been shown to reduce CVD mortality and mor-
bidity [2].
It has been demonstrated that low density lipoprotein-
cholesterol (LDL-C) reduction by statins substantially
reduces cardiovascular morbidity and mortality in both
primary and secondary prevention [3-5]. In 2004 the
National Cholesterol Education Program Adult Treatment
Panel III (NCEP-ATP III) guidelines were updated with
the addition of the optional goal of LDL-C < 70 mg/dL
(1.8 mmol/L) for those patients considered to be at very
high cardiovascular risk, mainly based on evidence from
Heart Protection Study (HPS) and The Pravastatin or
Atorvastatin Evaluation and Infection Therapy (PROVE
IT) trials [6-8]. Subsequently, Incremental Increase in
End Points Through Aggressive Lipid Lowering (IDEAL)
and Treating to New Targets (TNT) studies provided
evidence that more intensive versus moderate LDL-C
lowering treatment reduces the risk of major cardiovas-
cular events in patients with coronary artery disease
(CAD) [9,10]. A recent meta-analysis of several clinical
trials involving >170,000 patients revealed a dose-
dependent reduction in CVD morbidity and mortality
with LDL-C reduction [3]. Accumulating evidence with
respect to the beneficial effect on clinical outcome of in-
tensified statin therapy led the 2011 European Society of
Cardiology (ESC)/European Atherosclerosis Society
(EAS) guidelines to adopt LDL-C < 70 mg/dL (1.8 mmol/L)
as the main treatment goal in the subgroup of pa-
tients considered to be at very high cardiovascular risk
[2].
However, despite cumulating data from large clinical tri-
als demonstrating the benefit of LDL-C goal achievement,
which is recommended by the guidelines, a significant
treatment gap still remains, especially in patients consid-
ered at very high cardiovascular risk: National Cholesterol
Education Program Evaluation ProjecT Utilizing Novel
E-Technology (NEPTUNE) and Lipid Treatment Assess-
ment Project 2 (L-TAP 2) trials, which were conducted
between 2003 and 2007, showed that only 17.8%-34% of
very high risk patients attained the optional goal of
LDL-C < 70 mg/dL (1.8 mmol/L) [11,12]. It would be in-
teresting to assess lipid lowering management after the re-
lease of the 2011 ESC/EAS guidelines.
The present study aimed to investigate lipid-lowering
drug therapy used in every-day clinical practice, rates and
predictors of treatment target attainment among outpa-
tients with established CVD and/or diabetes mellitus
(DM), considered to be at very-high cardiovascular risk
in an urban area of Greece.Methods
This was a prospective, observational study, conducted be-
tween June 2011 and January 2012, in the county of
Achaia, Western Greece (327,316 inhabitants in 2001), in
17 private and 2 public (1 tertiary and 1 regional hospital)
outpatient cardiology clinics. We identified patients with
established CVD and/or DM, previously (at least 3 months
before baseline assessment) untreated with any lipid
lowering medication.
Patients with established CVD were considered those
with known CAD or non-coronary forms of atheroscler-
otic disease: peripheral arterial disease (PAD), abdominal
aortic aneurysm, cerebrovascular disease (ischemic stroke/
transient ischemic attack or >50% obstruction of a carotid
artery on ultrasound). CAD was defined as any of the
following: prior myocardial infarction (MI), prior percu-
taneous coronary intervention (PCI) or coronary artery
by-pass grafting (CABG), documented unstable angina,
positive non-invasive stress testing (nuclear imaging or
stress echocardiography) or ≥50% stenosis of at least one
major coronary artery on angiography. Presence of PAD
was determined by a history of intermittent claudication,
decreased pulses or bruit with ankle-brachial index <0.90,
or abnormal duplex ultrasound. DM was defined as pre-
existing diagnosis of DM made by a physician, use of
oral-hypoglycaemic agents or insulin or 2 fasting glucose
measurements >126 mg/dL [13].
Lipid profile assessment was performed at baseline (prior
to initiation of any lipid-lowering treatment) and at follow-
up. Data extracted from patient’s medical records were
collected and a case report form was completed. Only pa-
tients with complete lipid profile data [total cholesterol
(TC), LDL-C, high-density lipoprotein-cholesterol (HDL-C)
and triglycedides (TG)] at baseline and at follow-up were
included in analyses. Lipid lowering treatment choice as
well as lipid level monitoring and response to treatment
was at clinicians’ discretion. Lipid-lowering treatment was
kept constant until lipid profile assessment at follow-up
and patients with treatment changes were excluded from
analysis. Lipid assessment was performed in commercial
laboratories, in the context of usual clinical practice, under
fasting conditions. HDL-C was measured directly in the
serum. Friedewald formula was used for LDL-C calculation
[14]. Non-HDL-C was calculated as TC minus HDL-C.
Patients with known familial hypercholesterolemia or TG >
400 mg/dL, were excluded from the present analysis.
Primary treatment target was LDL-C < 70 mg/dL
(1.8 mmol/L), as the studied population was considered
to be at very high cardiovascular risk. Reiner Z, 2011 [2]
Non-HDL-C < 100 mg/dL (2.6 mmol/L) was a secondary
treatment target, in the subgroup of patients with DM
or increased TG levels (>150 mg/dL or 1.7 mmol/L) [2].
Lipid lowering regimens were classified by their %
LDL-C reduction efficacy, according to dose and kind of
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adjunct (combined therapy with ezetimibe and a statin
was considered to provide an incremental reduction in
LDL-C of 15%). As shown in Table 1, four groups of lipid
lowering regimens were identified: low, moderate, high
and very high-efficacy group, which included regimens
producing ≤30%, 31-45%, 46-55% and >55% LDL-C
reduction respectively [2]. Lipid lowering regimens with
at least low, moderate, high, or very high-efficacy were
considered as an appropriate treatment selection to achieve
the goal of LDL-C <70 mg/dL (1.8 mmol/L) at follow-up,
in patients with baseline LDL-C <100, 100–130, 131–150
and >150 mg/dL respectively.
Study’s protocol was approved by Patras University
Hospital Ethics Committee and all participants gave writ-
ten informed consent.
Statistical analysis
Categorical data are presented as frequencies and group
percentages and continuous data as means ± standard de-
viation. Two-sample t-test and the Fisher’s exact test were
used for comparison of continuous and categorical data
respectively. Multivariate logistic regression analysis (in a
backward elimination fashion, p > 0.1 for removal) was
used to assess independent predictors of LDL-C goal
attainment at follow-up, controlling for age, gender,
diabetes mellitus, presence of CAD, PAD, cerebrovascularTable 1 Classification of lipid lowering regimens used by thei
Low % LDL-C reduction Moderate % LDL-C reduc
Simvastatin 10 mg 10 mg + Eze
20 mg
40 mg
Fluvastatin 40 mg 80 mg
Rosuvastatin 5 mg
Pravastatin 20 mg 20 mg + Eze







Eze = ezetimibe.disease, smoking at baseline assessment, baseline LDL-C,
combined therapy with ezetimibe and a statin and very
high potency LDL-C lowering regimen. Fenofibrate and
n3 fatty acids use were additionally investigated as poten-
tial predictive factors of non-HDL-C goal attainment.
Models were tested for discriminative power by the C
statistic [area under the receiver operating characteristic
(ROC) curve]. All tests were 2-tailed and statistical
significance was considered for p-values < 0.05. Statistical
analyses were performed using SPSS for Windows
(version 16.0 SPSS Inc.Chicago II USA).Results
Study population
The study population consisted of 712 outpatients
(mean age 61.4 ± 10.4 years, 68.0% males). Patients’ base-
line characteristics and lipid values by LDL-C goal at-
tainment at follow-up are depicted in Table 2. Lipid
profile assessment at follow-up was performed at a me-
dian time of 3.0 (2.9-3.3 first to third quartile) months.
The majority (64.7%) of patients had prior CAD, 43.0%
of them were diabetics and 54.1% were current smokers,
with a mean LDL-C of 167.0 ± 35.6 mg/dL at time of
baseline assessment. As shown in Figure 1, at baseline
only 1(0.1%) patient had no lipid disorders, whereas 709
(99.7%) patients had LDL-C ≥70 mg/dL (1.8 mmol/L).r LDL-C lowering efficacy
tion High % LDL-C reduction Very high % LDL-C reduction
40 mg + Eze
80 mg
20 mg + Eze 80 mg + Eze
80 mg + Eze
20 mg 5 mg + Eze
10 mg + Eze
10 mg 20 mg + Eze
40 mg
40 mg + E
20 mg + Eze
40 mg 40 mg + Eze
10 mg + Eze
Table 2 Baseline characteristics of study population
Overall N = 712 LDL-C goal attainment N = 71 No LDL-C goal attainment N = 641 p-value
Age (years) 61.4 ± 10.4 63.2 ± 11.3 61.2 ± 10.3 0.1
Male gender 484 (68.0) 55 (77.5) 429 (66.9) 0.08
Cardiovascular risk factors
Prior CAD 461 (64.7) 53 (74.6) 408 (63.7) 0.07
Cerebrovascular disease 64 (9.0) 1 (1.4) 63 (9.8) 0.01
Abdominal aortic aneurysm 24 (3.4) 8 (11.3) 55 (8.6) 0.5
Peripheral arterial disease 63 (8.8) 8 (11.3) 55 (8.6) 0.5
Hypertension 458 (64.3) 44 (62.0) 414 (64.6) 0.7
Smoking 385 (54.1) 29 (40.8) 356 (55.5) 0.02
Diabetes mellitus 306 (43.0) 27 (38.0) 279 (43.5) 0.4
Family history of CAD 164 (23.0) 13 (18.3) 151 (23.6) 0.4
Lipid levels at baseline
TC (mg/dl) 248.5 ± 37.3 232.7 ± 36.9 250.3 ± 36.9 <0.001
LDL-C (mg/dl) 167.0 ± 35.6 150.1 ± 34.5 168.8 ± 35.3 <0.001
HDL-C (mg/dl) 45.7 ± 11.3 46.6 ± 10.1 45.6 ± 11.4 0.5
TG (mg/dl) 165.2 ± 68.4 170.7 ± 79.8 164.6 ± 67.0 0.5
Non HDL-C (mg/dl) 202.9 ± 37.7 186.1 ± 37.7 204.7 ± 37.3 <0.001
Data are expressed as means ± SD or n (%). CAD = coronary artery disease, TC = total cholesterol, LDL-C = low-density lipoprotein-cholesterol, HDL-C = high-density
lipoprotein-cholesterol, TG = triglycerides.
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Lipid lowering regimens used included the following antili-
pidemic drug classes: statins, fibrates, ezetimibe and n3
fatty acids. Statin monotherapy was the most frequently
prescribed regimen (65.3%) while 29.0% of patients were
prescribed a combination of statin and ezetimibe at the
baseline visit (Table 3). Simvastatin was the most frequentlyFigure 1 Lipid disorders rates before initiation of lipid modifying treaprescribed statin (Figure 2). The majority of patients re-
ceived a regimen of moderate LDL-C lowering efficacy
overall and in each baseline LDL-C subgroup of patients
(Figure 3). In total, only 237/712 (33.3%) of prescribed regi-
mens had appropriate LDL-C lowering efficacy, out of them
113/237(47.7%) comprised a combination of statin and
ezetimibe.tment and at follow-up.
Table 3 Lipid modifying treatment of study population
Overall N = 712 LDL-C goal attainment N = 71 No LDL-C goal attainment N = 641 p-value
Monotherapy 476 (66.9) 43 (60.6) 433 (67.6) 0.2
Statin 465 (65.3) 43 (60.6) 422 (65.8) 0.4
Fibrate 4 (0.6) 0 (0) 4 (0.6) 1.0
Ezetimibe 7 (1.0) 0 (0) 8 (1.2) 1.0
Combination therapy 236 (33.1) 28 (39.4) 208 (32.4) 0.2
Statin + Ezetimibe 182 (25.6) 22 (31.0) 160 (25.0) 0.3
Statin + Ezetimibe + n3 fatty acids 24 (3.4) 2 (2.8) 22 (3.4) 1.0
Statin + n3 fatty acids 24 (3.4) 2 (2.8) 22 (3.4) 1.0
Other 6 (0.8) 2 (2.8) 4 (0.6) 0.1
% LDL-C reduction efficacy 0.5
low 42 (5.9) 4 (5.6) 38 (5.9)
moderate 486 (68.3) 45 (63.4) 441 (68.8)
high 160 (22.5) 18 (25.4) 142 (22.2)
very high 24 (3.4) 4 (5.6) 20 (3.1)
Data are expressed as n (%).
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At follow-up the primary target of LDL-C < 70 mg/dL
(1.8 mmol/L) was achieved in 71(10.0%) patients. In
total 389 patients were eligible for the secondary target
of non HDL-C, which was achieved in 45(11.6%) of
them. Figure 1 shows rates of all lipid disorders at base-
line and at follow-up.
Multivariate analysis
In multivariate logistic regression analysis (AUC = 0.71,
95%CIs 0.65-0.77, p < 0.001) male gender, smoking, base-
line LDL-C and very high potency LDL-C lowering regi-
men emerged as independent predictors of LDL-C goal
attainment (OR = 1.88, 95%CIs 1.03-3.44, p = 0.04, OR =Figure 2 Lipid modifying medications used in the study population, c
prescribed treatments.0.57, 95%CIs 0.33-0.96, p = 0.04, OR = 0.98, 95%CIs 0.98-
0.99, p < 0.001 and OR = 2.21, 95%CIs 1.15-4.24, p = 0.02
respectively). There was a trend towards lower rates of
LDL-C goal attainment in patients with cerebrovascular
disease (OR = 0.15, 95%CIs 0.02-1.14, p = 0.07), as seen in
Table 4. Baseline LDL-C (OR = 0.98, 95%CIs 0.97-0.99,
p < 0.001) emerged as the only independent predictor of
non-HDL-C target attainment (AUC = 0.69, 95%CIs
0.62-0.77, p < 0.001), as seen in Table 5.
Discussion
This prospective, observational study provides insights
into the lipid lowering treatment of outpatients at very
high cardiovascular risk in Western Greece. The mainategory “other” includes regimens representing <1% of all
Figure 3 LDL-C lowering potency of lipid lowering therapy by baseline LDL-C, bars represent percentages within each baseline LDL-C
subgroup. Dotted pattern indicates treatment appropriateness as a function of baseline LDL-C to achieve the target of LDL-C<70 (1.8mmol/L)
at follow-up.
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ment of dyslipidemia seems to be unsatisfactory, since
most of the treated individuals failed to attain the LDL-C
target at follow-up b) In the majority of patients, pre-
scribed lipid lowering regimens had a suboptimal LDL-C
% reduction efficacy, as a function of baseline LDL-C, to
attain the goal of <70 mg/dl (1.8 mmol/L). c) Approxi-
mately 1/3 of patients were prescribed a combination of
statin and ezetimibe as first-line lipid-lowering treatment.
Our study points out a significant therapeutic gap in
treatment of patients at very high cardiovascular risk,
mainly due to prescription of suboptimal lipid lowering
regimens.
Based on several randomized clinical trials [3,9,10],
current ESC guidelines recommend LDL-C < 70 mg/dL
(1.8 mmol/L) as the primary treatment target in patientsTable 4 Predictors of LDL-C goal attainment
Initi
OR (95% CIs)






Cerebrovascular disease 0.14 (0.02-1.004)
Baseline LDL-C (mg/dl) 0.99 (0.98-0.99)
Combined therapy with statin and ezetimibe 1.15 (0.56-2.34)
Very high potency LDL-C lowering regimen 1.94 (0.84-4.49)
DM = diabetes mellitus, CAD = coronary artery disease, PAD = peripheral arterial diseat very high cardiovascular risk [2]. However, observa-
tional studies show that only a small proportion of pa-
tients with CAD achieve this goal [15-18]. A survey which
included longitudinal data from 18,656 participants,
showed that in U.S. achievement of LDL-C < 70 mg/dL
(1.8 mmol/L) improved from 2.4% to 17% (p < 0.0001) in
high-risk individuals and patients with CAD (3.4% to
21.4%, p < 0.0001) over the last decade, but still remains
insatisfactory [19]. Our findings are in the same line of
evidence, with the vast majority of patients failing to attain
LDL-C treatment target.
Several reasons may contribute to this observed treat-
ment gap. First, underestimation of cardiovascular risk
by the treating physician could have resulted in a poor
LDL-C target choice, leading to a lipid-lowering treat-
ment of suboptimal efficacy. As shown by Sager et al. inal model Final model
P-value OR (95% CIs) P-value
0.1 1.88 (1.03-3.44) 0.04
0.3
0.8
0.09 0.57 (0.33-0.96) 0.04
0.4
0.3
0.05 0.15 (0.02-1.14) 0.07
<0.001 0.99 (0.98-0.99) <0.001
0.7
0.1 2.21(1.15-4.24) 0.02
ase, LDL-C = low density lipoprotein-cholesterol.
Table 5 Predictors of non HDL-C goal attainment
Initial model Final model
OR (95% CIs) P-value OR (95% CIs) P-value
Male gender 1.04 (0.50-2.17) 0.9
Age 1.01 (0.98-1.05) 0.4
DM 0.78 (0.33-1.87) 0.6
Smoking 0.65 (0.31-1.36) 0.2
CAD 1.61 (0.75-3.45) 0.2 1.80 (0.95-3.42) 0.07
PAD 1.71 (0.62-4.66) 0.3
Cerebrovascular disease 0.64 (0.17-2.35) 0.5
Baseline LDL-C (mg/dl) 0.98 (0.97-0.99) 0.001 0.98 (0.97-0.99) <0.001
Combined therapy with statin and ezetimibe 1.92 (0.81-4.56) 0.1
Very high potency LDL-C lowering regimen 1.06 (0.36-3.10) 0.9
Fenofibrate 1.05 (0.34-3.42) 0.9
n3 fatty acids
DM = diabetes mellitus, CAD = coronary artery disease, PAD = peripheral arterial disease, LDL-C = low density lipoprotein-cholesterol.
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guideline-recommended low-density lipoprotein target
values, approximately 50% of high-risk patients did not
receive correct assignment of LDL target by their physi-
cians [20]. In addition, lack of awareness of the new, more
aggressive target of LDL-C < 70 mg/dL (1.8 mmol/L) by
the treating physicians, could have lead to the suboptimal
management of dyslipidemia in these patients [21]. How-
ever, failure to initiate a lipid lowering treatment of ap-
propriate efficacy is probably the main reason for the
observed low treatment goal attainment in our popula-
tion. Indeed, only 33.3% of patients were prescribed a
lipid lowering regimen of appropriate efficacy, finding is
in accordance with other observational studies [20-22].
It is of note that in our study, a significant proportion
of patients did not receive statin monotherapy but a
combination of statin and ezetimibe as starting treat-
ment. This can be explained by reluctance of physicians
to prescribe statins at high doses by the fear of side ef-
fects like myotoxicity [22] and by evidence supporting a
stronger LDL-C lowering effect of combination therapy
with statin and ezetimibe versus statin monotherapy
[23-26]. Statin treatment is in general considered safe
and serious adverse events are rare. However, mainly in
individuals with comorbidities, statin treatment may lead
to myopathy, a potentially fatal condition [2,22]. Statins
may also lead to transaminase elevation, which is dose-
dependent and usually reversible by reduction of dose
[2]. Ezetimibe provides when combined with a statin an
incremental reduction in LDL-C levels of 15-20% and
can be used as a combination with statins, in patients
with poor statin tolerance [2].
Male gender and treatment with very high potency
LDL-C lowering regimen favored primary treatment target
attainment, consistently with previous reports [17,27,28].In addition, our multivariate analysis showed that current
smokers and those with higher baseline LDL-C were less
likely to achieve LDL-C target, also in accordance with
other studies [11,17,21,29].
Furthermore, our study showed that success rate for
the secondary target of non-HDL-C was also very low.
Evaluation of success in attaining non-HDL-C goal in the
multinational L-TAP 2 study revealed a 34% success rate
among patients at very high cardiovascular risk, however
among those patients who failed to attain their LDL-C
target in the overall population only 11.2% achieved the
non-HDL-C target [12]. Therefore, the very low success
rate of non-HDL-C observed in our study might be ex-
plained by the poor LDL-C goal achievement.
The low treatment goal attainment among patients at
very high cardiovascular risk, underscores the need to
improve management of dyslipidaemia in those patients.
Treatment intensification with selection of appropriate
dose and drug as first-line treatment as well as dose ti-
tration when needed will help translating the important
benefits that statins demonstrated in large-scale clinical
trials to the real world.
Our study underscores the need to use a statin (at the
appropriate dose) as first-line treatment of dyslipidemia.
Otherwise, suboptimal dosing may lead to a high pro-
portion of patients not achieving the LDL-C goal. These
therapeutic options are clearly highlighted in the 2011
ESC/EAS guidelines, which recommend that a statin
should be the first-line pharmacological treatment of
dyslipidaemia, prescribed at a dose capable to provide
the percentage LDL-C reduction to achieve the LDL-C
target for patient’s individual CV risk level. If LDL-C tar-
get is not achieved after dose titration, statin combination
with bile acid sequestrant, nicotinic acid or cholesterol
absorption inhibitor may be considered [2]. In addition,
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Outcomes: Vytorin Efficacy International Trial (IMPROVE-
IT) and Efficacy and Safety of Alirocumab SAR236553
(REGN727) Versus Placebo on Top of Lipid-Modifying
Therapy in Patients With High Cardiovascular Risk and
Hypercholesterolemia (ODYSSEY Combo I) will provide
important information on the role of combined lipid-
lowering therapy in the treatment of patients at high car-
diovascular risk.
Several limitations apply to our study. As we only stud-
ied patients managed by a cardiologist our findings may
not reflect the practices of other physicians. Furthermore,
our results may underestimate the prevalence of lipid-
lowering treatment failure in the general population, as
selection of participating physicians and patients was
based on their consent and complete lipid profile avail-
ability. In addition, as our study was conducted shortly
after the release of 2011 ESC/EAS guidelines, we cannot
exclude the existence of potential temporal trend in per-
ception of guidelines and management of dyslipidaemias
by the treating physicians. Allowing a longer interval be-
fore recheck lipid levels is probably considered as an
“off-label” practice. However, no evidence based informa-
tion exists and low rates of goal attainment at follow-up,
could certainly not be attributed to inadequate treatment
length. We did not use a central laboratory for lipid mea-
surements; however this rather reflects the real-life clin-
ical practice. Finally, adherence to treatment was not
monitored.
Conclusions
First-line management of dyslipidemia among very-high
cardiovascular risk outpatients in Western Greece is unsat-
isfactory, with the majority of treated individuals failing to
attain the LDL-C and non-HDL-C targets. This observed
treatment gap although disappointing, translates into an
opportunity to ameliorate clinical outcome of such patients.
Therefore, strategies to improve management of dyslipid-
emia, such as intensification of first-line statin treatment,
are necessary.
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